Everolimus (Afinitor) has been recommended by the National Institute for Health and Care Excellence (NICE) for use by NHS England for people with advanced renal cell carcinoma (RCC) that has progressed during or after treatment with a vascular endothelial growth factor (VEGF) targeted therapy. This decision has been made following a reconsideration of everolimus by NICE after the closure of the original Cancer Drugs Fund (CDF) in April last year. Previously, NICE had not recommended everolimus for use within the NHS as a second-line treatment, which was being funded via the CDF.

This is fantastic news for advanced kidney cancer patients. This decision increases the arsenal of drugs available to oncologists, enabling them to select the most effective drug for individual patients when first-line treatment with targeted therapies fails. This decision also gives hope to many people with advanced kidney cancer, who have come to the end of the line with respect to treatment options routinely funded by the NHS, and who are unable to take VEGF targeted therapy or immunotherapy.

KCSN would like to thank all those patients who contributed to the reconsideration of everolimus by NICE, and who represented the views and opinions of the wider kidney cancer community. We would also like to thank all the clinicians who fought hard to improve access to second-line treatment on behalf of their patients – we are STRONGER TOGETHER!

Read the NICE press release here

Read PharmaTimes article here